EGFR and head and neck squamous cell carcinoma: In addition to previous studies focusing on anti-EGFR therapy, consideration of dual FGFR and EGFR (or EGFR-related) targeting appears to be critical for optimizing therapy in HNSCC by effectively deactivating survival- and EMT-promoting bypass signals.